Actinium Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Market Information
Our common stock is listed for quotation on the NYSE American under the symbol “ATNM”.
Holders
As of March 28, 2025, there were 31,195,891 shares of common stock issued and outstanding, which were held by approximately 100 holders of record. There are no shares of preferred stock outstanding.
Dividends
We have never declared or paid any cash dividends on our common stock. For the foreseeable future, it is expected that earnings, if any, generated from our operations will be used to finance the growth of our business, and that no dividends will be paid to holders of our common stock. The decision to pay dividends is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, capital requirements, and other factors that our Board of Directors deems relevant.
Securities Authorized for Issuance under Equity Compensation Plans
We currently have one equity compensation plan. The Company’s 2019 Amended and Restated Stock Plan, (the “2019 Plan”) has an expiration date of October 18, 2029 and the number of shares of our common stock authorized under the plan for grant to employees, directors and consultants is 9,333,333 shares.
We had two equity compensation plans that expired on September 9, 2023; the Company’s Amended and Restated 2013 Stock Plan and the Company’s 2013 Equity Incentive Plan.
The following table indicates shares of common stock authorized for issuance under our equity compensation plans as of December 31, 2024:
| Plan category | Number of securities to be issued upon exercise of outstanding options and restricted stock units (1) | Weighted- average exercise price of outstanding options (2) | Number of securities remaining available for future issuance |
|---|---|---|---|
| Equity compensation plans approved by security holders | 5,437,413 | $6.48 | 4,322,664 |
| Equity compensation plans not approved by security holders | - | - | - |
| Total | 5,437,413 | $6.48 | 4,322,664 |
| (1) | Includes shares issuable upon the conversion of outstanding restricted stock units (“RSUs”). |
| (2) | The Weighted Average Exercise Price column does not include an amount for outstanding RSUs. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.